11/21
08:05 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
11/21
08:05 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating. They now have a $4.00 price target on the stock.
11/21
04:51 am
sage
Rating for SAGE
Low
Report
Rating for SAGE
11/21
04:51 am
sage
Rating for SAGE
Low
Report
Rating for SAGE
11/20
01:16 pm
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
11/20
08:32 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/20
08:18 am
sage
Rating for SAGE
Medium
Report
Rating for SAGE
11/20
08:18 am
sage
Rating for SAGE
Medium
Report
Rating for SAGE
10/30
02:49 pm
sage
Rating for SAGE
Low
Report
Rating for SAGE
10/30
02:49 pm
sage
Rating for SAGE
Low
Report
Rating for SAGE
10/30
12:01 pm
sage
Rating for SAGE
Medium
Report
Rating for SAGE
10/30
12:01 pm
sage
Rating for SAGE
Medium
Report
Rating for SAGE
10/30
08:00 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
High
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
10/30
05:29 am
sage
Rating for SAGE
High
Report
Rating for SAGE
10/30
05:29 am
sage
Rating for SAGE
High
Report
Rating for SAGE
10/17
09:18 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
10/17
08:53 am
Rating for SAGE
Report
Rating for SAGE
10/17
08:53 am
Rating for SAGE
Report
Rating for SAGE
10/10
09:36 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "market perform" rating re-affirmed by analysts at Raymond James.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "market perform" rating re-affirmed by analysts at Raymond James.
10/10
09:36 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "market perform" rating re-affirmed by analysts at Raymond James.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "market perform" rating re-affirmed by analysts at Raymond James.
10/10
08:58 am
sage
Rating for SAGE
Low
Report
Rating for SAGE
10/10
08:58 am
sage
Rating for SAGE
Low
Report
Rating for SAGE
10/9
09:55 am
sage
Rating for SAGE
Low
Report
Rating for SAGE
10/9
09:55 am
sage
Rating for SAGE
Low
Report
Rating for SAGE
10/9
08:33 am
sage
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.